Gain Therapeutics (GANX)
Develops allosteric medicines and rexaceract for Parkinson’s disease.
Something off on this page? Send us feedback.
Develops allosteric drug candidates through its Magellan platform, centered on rexaceract for Parkinson’s disease. The clinical portfolio is concentrated in this orally administered GCase-targeting program.
Based in Bethesda, Maryland, research combines AI, physics-based methods, and supercomputing in the Magellan platform to identify allosteric binding sites and potential drug candidates. Discovery work spans neurodegenerative and lysosomal-storage diseases, metabolic disease, and solid tumors, while the clinical portfolio is centered on rexaceract, formerly GT-02287.
Rexaceract is an orally administered, brain-penetrant allosteric modulator intended to restore GCase function in Parkinson’s disease, with or without a GBA1 mutation. FDA authorization of the U.S. IND supports planned clinical development in the United States, Australia, and Europe. Progress depends on clinical execution, regulatory interaction, enrollment across that trial footprint, and advancing further Magellan-derived candidates.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Dec 19, 2025 | Roth Capital | Target | Target: — | Target: $10 |
| Dec 1, 2025 | H.C. Wainwright | Target | Target: — | Target: $8 |
| Oct 7, 2025 | Maxim Group | Reiterate | Rating: —Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.1M · Total debt $609.9K · Total assets $15.4M · Shareholders' equity $11.3M
- Revenue
- $0
- Operating income
- −$4.7M
- Net income
- −$4.7M
No dividends on record.
| Institutions | 19.84% | 8.66M shares | |
|---|---|---|---|
| 54 holders · as of Jun 30, 2026 | |||
| Other | 80.16% | 34.98M shares | |
| remainder | |||
43.64M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Marshall Wace, LLPInstitution | 4.41% | 1.92M | as of Jun 30, 2026 |
Potomac Capital Management, Inc.Institution | 2.17% | 946,400 | as of Jun 30, 2026 |
Gsa Capital Partners LLPInstitution | 1.45% | 632,131 | as of Jun 30, 2026 |
Jones Financial Companies LLLPInstitution | 1.39% | 608,592 | as of Jun 30, 2026 |
Cambridge Investment Research Advisors, Inc.Institution | 1.30% | 568,645 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Denali Therapeutics
LRRK2-PD and GCase Parkinson’s programs overlap directly
- AbbVie
24-hour subcutaneous levodopa infusion for advanced Parkinson’s disease
- Amneal Pharmaceuticals
Approved oral carbidopa/levodopa extended-release Parkinson’s therapy
- Supernus Pharmaceuticals
Wearable infusion treatment for advanced Parkinson’s motor fluctuations
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Gain Therapeutics | $1.88 | −3.85% | $83.2M | — | — | — | — |
| Denali Therapeutics | $20.60 | −4.64% | $3.43B | — | — | 951.2 | — |
| AbbVie | $264.83 | −0.15% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Amneal Pharmaceuticals | $19.00 | −2.57% | $6.23B | 40.0 | 19.1 | 2.0 | +9.9% |
| Supernus Pharmaceuticals | $43.47 | −0.64% | $2.54B | — | 15.0 | 3.1 | +32.4% |
| Median | 57.4 | 17.4 | 5.2 | +10.2% |